MTOR and colorectal carcinoma: Thus, the power of our current study is that combination of a genomic based approach with in vitro and in vivo validation using a preclinical model of colorectal cancer to show that the combination of oxaliplatin and a mTOR inhibitor is synergistic can be considered in patients with CRC liver metastasis.